Partnerships Updates and Statements

01.17.2025

The Pfizer Foundation Provides $15 Million Investment to Improve Breast Cancer Care in Sub-Saharan Africa

01.30.2023

Pfizer and International Trachoma Initiative Deliver One Billionth Zithromax® Dose Toward Trachoma Elimination by 2030

12.13.2022

Pfizer to Provide U.S. Government with an Additional 3.7 Million Treatment Courses of PAXLOVID™ to Help Combat COVID-19

06.13.2022

Pfizer, MorphoSys and Incyte Enter into Clinical Trial Collaboration for Monjuvi® (tafasitamab-cxix) in Combination with TTI-622, a Fusion Protein Directed Against CD47

06.05.2022

Pfizer Presents First Data from Planned Interim Analysis of Pivotal Phase 2 MagnetisMM-3 Trial of BCMA-CD3 Bispecific Antibody Elranatamab Under Investigation for Relapsed/Refractory Multiple Myeloma

02.25.2022

FDA Accepts for Review Pfizer’s Supplemental Application for ABRILADA™ (adalimumab-afzb) InterchangeabilityFDA Accepts for Review Pfizer’s Supplemental Application for ABRILADA™ (adalimumab-afzb) Interchangeability

02.24.2022

Pfizer and BioNTech Receive Positive CHMP Opinion for COVID-19 Vaccine Booster in Adolescents 12 through 17 Years of Age in the European Union

12.20.2021

Pfizer and BioNTech to Provide European Union More Than 200 Million Additional Doses of COMIRNATY® to Help Meet Continued Need for Vaccine Supply

12.17.2021

Pfizer and BioNTech Provide Update on Ongoing Studies of COVID-19 Vaccine

09.17.2019

TrialSpark and Pfizer collaborating to improve speed and access to clinical trials